Literature DB >> 30375024

Redox imbalance and IL-17 responses in memory CD4+ T cells from patients with psoriasis.

Behnaz Esmaeili1,2, Parvin Mansouri3, Amir Hossein Doustimotlagh4, Maryam Izad1,5,6.   

Abstract

All stages of the inflammatory process involved in T cell-mediated chronic skin disorders like psoriasis are affected by redox imbalance. On the other hand, Th17 cells have a critical role in the pathogenesis of psoriasis. In this study, we evaluated redox status in memory CD4 + T cells and plasma of patients with psoriasis and its correlation with IL-17 response. To this end, memory T cells were isolated from 10 patients with psoriasis and 10 controls. Intracellular Glutathione (GSH), reactive oxygen species (ROS) and superoxide as well as IL-17 were measured using flow cytometry. Plasma total anti-oxidant capacity (TAC) was quantified by ferric reducing ability of plasma (FRAP) assay. The expression of catalase (CAT), superoxide dismutase 1(SOD1), superoxide dismutase 2 (SOD2), nuclear factor, erythroid 2 like 2 (NFE2L2) and cytochrome b-245 beta chain (CYBB) genes were analysed using real-time PCR. Our results showed an increased intracellular ROS production in memory CD4 + T cells of patients compared to controls, (P = 0.04). Furthermore, a significant decrease in expression of catalase gene was found in patients, (P = 0.02). However, no significant differences were observed for intracellular GSH, IL-17 and TAC levels between patients and controls. Also, no correlation was seen between the intracellular IL-17 level and intracellular ROS, GSH and catalase gene expression levels. Collectively, we found an increased ROS production in stimulated memory T cells of patients that could be due to reduced expression of catalase gene. However, it seems that these redox abnormalities have no relationship with IL-17 response in memory T cells.
© 2018 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Keywords:  IL-17; Psoriasis; catalase; redox

Mesh:

Substances:

Year:  2018        PMID: 30375024     DOI: 10.1111/sji.12730

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  The Serum Level of Oxidative Stress and Antioxidant Markers in Patients with Psoriasis: A Cross-sectional Study.

Authors:  Safoura Shakoei; Manouchehr Nakhjavani; Hossein Mirmiranpoor; Mohana Alinejad Motlagh; Arghavan Azizpour; Robabeh Abedini
Journal:  J Clin Aesthet Dermatol       Date:  2021-07-01

Review 2.  Immunological Memory of Psoriatic Lesions.

Authors:  Agnieszka Owczarczyk Saczonek; Magdalena Krajewska-Włodarczyk; Marta Kasprowicz-Furmańczyk; Waldemar Placek
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

3.  Redox Imbalance in CD4+ T Cells of Relapsing-Remitting Multiple Sclerosis Patients.

Authors:  Mohammad Javad Tavassolifar; Abdorreza Naser Moghadasi; Behnaz Esmaeili; Omid Sadatpour; Mohammad Vodjgani; Maryam Izad
Journal:  Oxid Med Cell Longev       Date:  2020-12-02       Impact factor: 6.543

Review 4.  Update on the etiopathogenesis of psoriasis (Review).

Authors:  Daciana Elena Branisteanu; Catalina Cojocaru; Roxana Diaconu; Elena Andrese Porumb; Anisia Iuliana Alexa; Alin Codrut Nicolescu; Ilarie Brihan; Camelia Margareta Bogdanici; George Branisteanu; Andreea Dimitriu; Mihail Zemba; Nicoleta Anton; Mihaela Paula Toader; Adrian Grechin; Daniel Constantin Branisteanu
Journal:  Exp Ther Med       Date:  2022-01-05       Impact factor: 2.447

Review 5.  The Involvement of Oxidative Stress in Psoriasis: A Systematic Review.

Authors:  Elena-Codruța Dobrică; Matei-Alexandru Cozma; Mihnea-Alexandru Găman; Vlad-Mihai Voiculescu; Amelia Maria Găman
Journal:  Antioxidants (Basel)       Date:  2022-01-29

Review 6.  Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies.

Authors:  Jiangmei Xu; Hao Chen; Haisheng Qian; Fei Wang; Yunsheng Xu
Journal:  J Nanobiotechnology       Date:  2022-10-14       Impact factor: 9.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.